|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||29.53 - 29.83|
|52 Week Range||19.67 - 29.83|
|PE Ratio (TTM)||53.11|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
BSX's EPS estimate for 3Q17 represents YoY (year-over-year) growth in the range of 9%–16%. In 2Q17, Boston Scientific registered EPS growth of 18.5% YoY.
Boston Scientific's (BSX) 3Q17 revenues are expected to come in at $2.21 billion, representing YoY (year-over-year) growth of ~4.8%.
BSX stock has been performing well recently, and investor confidence appears to have ridden on innovative product launches and strong 2Q17 results.
Although Boston Scientific's (BSX) recent $435-million acquisition of Symetis SA might drive its IC business, the company's full recovery post a primary product recall may however, take time.
With hundreds of workers missing after Hurricane Maria devastated the island, health-care and other firms turned to the airwaves.
Boston Scientific (BSX) is gaining traction on product launch and accretive acquisitions. Yet an unfavorable currency movement is a major dampener.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting BSX. Over the last one-month, outflows of investor capital in ETFs holding BSX totaled $6.94 billion.
A pacemaker for the brain can be used to treat symptoms of neurological disorders like Parkinson’s Disease.
Boston Scientific's (BSX) Apama Medical addition is expected to strengthen its suite of arrhythmia solutions under the Electrophysiology sub-segment.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting BSX. Over the last one-month, outflows of investor capital in ETFs holding BSX totaled $3.92 billion.
Boston Scientific Corporation (NYSE:BSX) is trading with a trailing P/E of 50.5x, which is higher than the industry average of 42.6x. While this makes BSX appear like a stock toRead More...
The deal represents a healthy return for venture-capital investors in the maker of atrial fibrillation treatment products.
The PAS2 study, which is a post-approval clinical trial, was conducted at 27 sites across the United States and Canada.
According to the recommendations of 24 brokerage companies surveyed by Reuters, ~75% of the analysts provided a “buy” rating for BSX stock.
Boston Scientific is focused on accelerating the company’s growth by expanding across high-growth markets outside the United States.
On September 25, Boston Scientific (BSX) announced the launch of the Resonate family of ICD and CRT-D systems. The devices are approved by the FDA for conditional use in the MRI environment.
On September 19, 2017, Boston Scientific announced new data from its MultiSENSE (Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients) study.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting BSX. Over the last one-month, outflows of investor capital in ETFs holding BSX totaled $4.20 billion.